Yesterday it was reported that the PRESIDENT & CEO of Tandem Diabetes Care (TNDM), John Sheridan, exercised options to sell 33,200 TNDM shares at $16.30 a share, for a total transaction value of $3.39M.
Following John Sheridan’s last TNDM Sell transaction on January 03, 2019, the stock climbed by 73.5%. In addition to John Sheridan, 4 other TNDM executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes Care’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $97.93 million and GAAP net loss of -$14,867,000. In comparison, last year the company earned revenue of $93.26 million and had a GAAP net loss of $1.51 million. The company has a one-year high of $110.80 and a one-year low of $43.69. Currently, Tandem Diabetes Care has an average volume of 585.02K.
Based on 13 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $118.23, reflecting a -10.8% downside. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy TNDM with a $125.00 price target.
In the last 30 days, insiders have sold $6.45M worth of TNDM shares and purchased $5,180 worth of TNDM shares. The insider sentiment on Tandem Diabetes Care has been negative according to 73 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
John Sheridan’s trades have generated a 18.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.